Serum Prealbumin and Retinol-Binding Protein Concentrations in Japanese-Type Familial Amyloid Polyneuropathy

1988 ◽  
Vol 28 (4) ◽  
pp. 191-193 ◽  
Author(s):  
Shin’ichi Shoji ◽  
Shin’ichi Nakagawa
Keyword(s):  
Binding Protein ◽  
Familial Amyloid Polyneuropathy ◽  
Retinol Binding Protein ◽  
Amyloid Polyneuropathy

scholarly journals Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism

2021 ◽  
Vol 22 (9) ◽  
pp. 4429
Author(s):  
Jin-Beom Si ◽  
Bokyung Kim ◽  
Jin Hae Kim
Keyword(s):  
Cerebrospinal Fluid ◽  
Thyroid Hormone ◽  
Human Plasma ◽  
Structural Features ◽  
Familial Amyloid Polyneuropathy ◽  
Systemic Amyloidosis ◽  
Retinol Binding Protein ◽  
Senile Systemic Amyloidosis ◽  
Amyloid Polyneuropathy ◽  
Amyloid Cardiomyopathy

Transthyretin (TTR) is an essential transporter of a thyroid hormone and a holo-retinol binding protein, found abundantly in human plasma and cerebrospinal fluid. In addition, this protein is infamous for its amyloidogenic propensity, causing various amyloidoses in humans, such as senile systemic amyloidosis, familial amyloid polyneuropathy, and familial amyloid cardiomyopathy. It has been known for over two decades that decreased stability of the native tetrameric conformation of TTR is the main cause of these diseases. Yet, mechanistic details on the amyloidogenic transformation of TTR were not clear until recent multidisciplinary investigations on various structural states of TTR. In this review, we discuss recent advancements in the structural understanding of TTR misfolding and amyloidosis processes. Special emphasis has been laid on the observations of novel structural features in various amyloidogenic species of TTR. In addition, proteolysis-induced fragmentation of TTR, a recently proposed mechanism facilitating TTR amyloidosis, has been discussed in light of its structural consequences and relevance to acknowledge the amyloidogenicity of TTR.

586-P: Vitreous and Serum Measurements of Retinol Binding Protein 3 in the Clinical Evaluation of Diabetic Retinopathy

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 586-P
Author(s):  
WARD FICKWEILER ◽  
HISASHI YOKOMIZO ◽  
KYOUNGMIN PARK ◽  
SAMANTHA M. PANIAGUA ◽  
I-HSIEN WU ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Clinical Evaluation ◽  
Binding Protein ◽  
Retinol Binding Protein

scholarly journals Plasma retinol-binding protein 4 in the first and second trimester and risk of gestational diabetes mellitus in Chinese women: a nested case-control study

2020 ◽  
Vol 17 (1) ◽  
Author(s):  
Chuyao Jin ◽  
Lizi Lin ◽  
Na Han ◽  
Zhiling Zhao ◽  
Zheng Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Gestational Diabetes ◽  
Gestational Diabetes Mellitus ◽  
Binding Protein ◽  
First Trimester ◽  
Retinol Binding Protein ◽  
Second Trimester ◽  
Retinol Binding Protein 4 ◽  
Plasma Retinol

Abstract Background To assess the association between plasma retinol-binding protein 4 (RBP4) levels both in the first trimester and second trimester and risk of gestational diabetes mellitus (GDM). Methods Plasma RBP4 levels and insulin were measured among 135 GDM cases and 135 controls nested within the Peking University Birth Cohort in Tongzhou. Multivariable linear regression analysis was conducted to assess the influence of RBP4 levels on insulin resistance. Conditional logistic regression models were used to compute the odds ratio (OR) and 95% confidence interval (CI) between RBP4 levels and risk of GDM. Results The GDM cases had significantly higher levels of RBP4 in the first trimester than controls (medians: 18.0 μg/L vs 14.4 μg/L; P < 0.05). Plasma RBP4 concentrations in the first and second trimester were associated with fasting insulin, homeostasis model assessment for insulin resistance (HOMA-IR), and the quantitative insulin sensitivity check index (QUICKI) in the second trimester (all P < 0.001). With adjustment for diet, physical activity, and other risk factors for GDM, the risk of GDM increased with every 1-log μg/L increment of RBP4 levels, and the OR (95% CI) was 3.12 (1.08–9.04) for RBP4 in the first trimester and 3.38 (1.03–11.08) for RBP4 in the second trimester. Conclusions Plasma RBP4 levels both in the first trimester and second trimester were dose-dependently associated with increased risk of GDM.

Sign in / Sign up

Export Citation Format

Share Document